<DOC>
	<DOCNO>NCT00477451</DOCNO>
	<brief_summary>We develop Staccato™ Alprazolam treatment Panic attack associate panic disorder . This study provide initial assessment efficacy , continue describe tolerability pharmacokinetics , single inhale dose Staccato Alprazolam doxapram-induced panic attack patient panic disorder .</brief_summary>
	<brief_title>Staccato Alprazolam Panic Attack</brief_title>
	<detailed_description>The study conduct multiple center . A total 42 male female panic disorder patient study . The first 6 subject receive Staccato Alprazolam 1 mg open label validate dose selection . The remain 36 subject treat either Staccato Alprazolam choose dose ; Staccato Placebo double blind , randomize order .</detailed_description>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>1 . Subjects meet DSMIV criterion panic disorder , without agoraphobia . 2 . Subjects least one panic attack per week four week prior start treatment and/or Mobility Inventory Score 3.3 ( alone ) 2.5 ( accompany ) . 3 . Male female subject Englishspeaking 18 55 year age . 4 . Female subject pregnant , surgically sterile 2 year postmenopausal . If childbearing potential , must use medicallyaccepted method birth control agree continue use method least 30 day study ( i.e. , barrier method spermicide , steroidal contraceptive [ oral , transdermal , implanted , include DepoProvera ; contraceptive must use conjunction barrier method ] , intrauterine device ) . 5 . Subjects medically healthy ( i.e . without clinically significant unstable medical condition asthma , coronary artery disease , renal insufficiency , etc . ) 6 . Subjects able give inform consent participation . 7 . Subjects able withdrawn current panic disorder medication ineffective . 1 . Subjects meet DSMIV criterion substance abuse dependence within six month study entry must exclude . 2 . Subjects baseline Acute Panic Inventory ( 22 item test ) score 41 high test day must exclude . 3 . Subjects take benzodiazepine , SSRIs , medication effective prevention treatment patient 's panic disorder ( i.e. , patient withdrawn medication work purpose entry study ) must exclude . 4 . Subjects clinically depress must exclude . 5 . Subjects receive investigational drug within 30 day ( within 5 half life investigational drug ) prior test day must exclude . 6 . Subjects epilepsy convulsive disorder must exclude . 7 . Subjects history allergy intolerance benzodiazepine relate drug ( alprazolam , lorazepam , diazepam , etizolam , clonazepam , adinazolam ) must exclude . 8 . Subjects test positive alcohol positive urine drug screen illicit disallow drug must exclude . Subjects refrain consume alcohol least 48 hour prior dose . 9 . Female subject breastfeed positive pregnancy test must exclude . 10 . Subjects disease condition , history , physical examination , laboratory abnormality investigator 's opinion , would present undue risk subject , may confound interpretation study result must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Staccato™ Alprazolam , Panic Attack</keyword>
</DOC>